Plexin domain containing 2 (PLXDC2) is expressed on the surface of several cell types, such as macrophages, dendritic or epithelial cells. Its activation reduces oxidative stress and rebalances the immune response and decreases inflammation. Its activation has been seen to improve disease severity in models of rheumatoid arthritis, while its blockade or loss exacerbates the severity of dextran sulfate sodium (DSS)-induced colitis. Researchers hence tested the PLXDC2 agonist PX-04 (Landos Biopharma Inc.) in a DSS-induced murine model of colitis.
Shanghai and New Jersey-based Lianbio Co. Ltd. has made its second in-licensing deal in a week. This time, it obtained rights for omilancor and NX-13, both under development by Landos Biopharma Inc. for the potential treatment of ulcerative colitis (UC) and Crohn’s disease (CD) – plus eosinophilic esophagitis, for omilancor – in greater China, South Korea and seven ASEAN countries as part of a $218 million deal.
Shanghai and New Jersey-based Lianbio Co. Ltd. has made its second in-licensing deal in a week. This time, it obtained rights for omilancor and NX-13, both under development by Landos Biopharma Inc. for the potential treatment of ulcerative colitis (UC) and Crohn’s disease (CD) – plus eosinophilic esophagitis, for omilancor – in greater China, South Korea and seven ASEAN countries as part of a $218 million deal.
Of the three companies launching IPOs Feb. 4, one struggled mightily, another posted double-digit gains while the third ended the day flat. Shares of Landos Biopharma Inc. (NASDAQ:LABP) dropped 25%, to $12 each, on their first day of trading. Sana Biotechnology Inc. (NASDAQ:SANA) had the strongest first day of trading as shares closed 40.4% higher at the close at $35.10. Sensei Biotherapeutics Inc. (NASDAQ:SNSE) saw its IPO launch roughly break even on its first day of trading, closing with only a half-point gain at $18.90.
